⭐️Clinical Insights at @IASLC/@ASCO #NACLC25: Metastatic EGFR+ 🫁NSCLC from MARIPOSA and FLAURA2 🤩Listen as our expert panelists take a full dive into these trials! #OncTwitter #LungCancer #lcsm @JSabari @lungoncdoc @EddieSantosMD @AlexSpiraMDPhD 🔗

This is the algorithm we touched on/walked through during our discussion with @rutikamehtaMD for Her2+ GEJ/Gastric adenocarcinoma! #OncTwitter #MedTwitter @gotoPER

Awesome article written by one of our ⭐️ star chiefs Rafa! Check out #ASH25 highlights in Lymphoma! @AgrimaMianMD @hemeoncfellow @HemOncFellows @ccfhemonc @CCF_IMCHIEFS #OncTwitter

🚨 #ASH25 Data 👉transforming lymphoma care! 🔷POLARIX 5-year update supports pola-R-CHP in frontline DLBCL 🔷Bispecifics advancing earlier 🔷Nivo-AVD superior in Hodgkin lymphoma 🔷Emerging BCL2 inhibitors for MCL #OncTwitter #MedTwitter Full article:

Breast cancer research highlights from 2025 🧬 A non-exhaustive overview of impactful clinical trials and liquid biopsy work presented at ESMO & SABCS. ADCs, maintenance, MRD, and molecular response continue to shape where the field is headed. Still a lot more to learn.

#OncTwitter #regulatory #bcsm 📣 #FDA has approved trastuzumab deruxtecan + pertuzumab for 1st-line tx of adults w/ HER2+ unresectable or #MetastaticBreastCancer based on DB-09 trial: 🏆44% ⬇️ in risk of progression/death vs THP (mPFS: 40.7 vs 26.9 mos). ⚠️ ILD ~12%

As we gear up for #GI26, we discussed testing and the current SoC for HER2+ advanced/metastatic GEJ/Gastric cancer with @rutikamehtaMD: Full discussion: ⭐️ https://t.co/otnkXXYed0 ⭐️ https://t.co/XoYcPtw3Gf ⭐️ Also on “Oncology Brothers” podcast #lcsm #OncTwitter @OncUpdates

Great news for patients. Now we have to decide how to optimally use this combo! FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer! Maintenance and added value of P are key issues. ⁦@OncoAlert⁩

Looking forward to an Evening with @OncBrothers #OncBros at #GI26

📢Abstract titles released for #GI26! Looking forward to hearing from experts in #GIOnc on practice changing abstracts! @DrShubhamPant @CentralParkWMD @DrR_DUNNE @TimothyJBrownMD @AnwaarSaeed3 @NVijayvergiaMD @OncBrothers #gism #OncTwitter #MedTwitter #CommunityOncology

TDXd + Pertuzumab now @US_FDA ✅ in 1L metastatic Her2+ breast cancer based off #DestinyBreast09: vs THP: - mPFS 40.7 vs 26.9mos (HR: 0.56) - 15.2% vs 8.5% CRs - Serious TAES: 27% vs 25.1%. Any Gr ILD 12.1% vs 1%. 2 Gr5 ILDs! #OncTwitter #bcsm @OncoAlert @OncUpdates

The PARADIGM trial in AML is a groundbreaking Phase 2 study that compared Aza-Ven versus standard intensive chemotherapy (7+3 or CPX-351) in fit, ND AML patients, showing significantly longer EFS and higher response rates with Aza-Ven #leusm #ASH25

Also bringing in our 🩸 #Hematology experts from #ASH25 What studies would you highlight as ⭐️Best of 2025?! CLL @bitafakhri @calliecoombsmd Lymphoma: @DrAEvens @AnnaSureda5 Leukemia: @beatalleukemia @GCC_Cortes @FadiHaddad_MD Myeloma: @VincentRK @Myeloma_Doc

Starting off with our recent experts at #SABCS2025! What was your favorite research highlights in #BreastCancer 🤔 @ErikaHamilton9 @PTarantinoMD @sdent_cardioonc @DrSGraff @jhaveri_komal @KalinskyKevin @SPremji7866 @DrSAHaddad @stolaney1 #bcsm

🚨#OncTwitter/#HemeTwitter IT’S TIME FOR THE OFFICIAL #Bestof2025 IN #Hematology & #Oncology🚨 What studies surprised you the most and should make the list 🤔 Let’s work together to build the ultimate Best of 2025 list! 🤝 #MedTwitter #MedX @OncoAlert @Larvol @OncBrothers

This is the table we’ve used (common AEs, black📦warnings, & dose⬇️) during our ToxCheck 🗣️ on ADCs in #LungCancer with @sands_jacob: 1. TDXd: 🫁, Nausea, fatigue 2. DatoDXd: Stomatitis, dry 👀, 🫁 3. TelisoV: Neuropathy #OncTwitter #MedTwitter #lcsm @OncoAlert @OncUpdates

ToxCheck: AEs for ADCs approved in Lung Cancer & how to manage them with @sands_jacob: ✅ TDXd: HER2+ ✅ DatoDXd: EGFR+ ✅ TelisoV: C-MET Full 🗣️: ⭐️ https://t.co/qG1al4sR1b ⭐️ Also on “Oncology Brothers” podcast #OncTwitter @OncUpdates @OncoAlert #lcsm

🌟Highly encourage listening to this discussion between @OncBrothers and Dr. Beltrami-Moreira from @OSUCCC_James on ferritin abnormalities! Available on our website and the “Oncology Brothers” podcast! #HemeTwitter #MedTwitter #CommunityOncology #MedX https://t.co/iI1gPNXktR